We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Integrated LAMP and Immunoassay Platform Detect Diarrheal Disease

By LabMedica International staff writers
Posted on 26 Sep 2018
Print article
Image: The SpinDx system (Photo courtesy of Sandia National Laboratories).
Image: The SpinDx system (Photo courtesy of Sandia National Laboratories).
The challenges of diagnosing infectious disease, especially in the developing world, and the shortcomings of available instrumentation have exposed the need for portable, easy-to-use diagnostic tools capable of detecting the wide range of causative microbes while operating in low resource settings.

There are approximately 1.7 billion cases of diarrheal disease globally each year, and the syndrome is frequently caused by infections. Children are particularly vulnerable; diarrheal disease kills more than half a million children worldwide each year, and is the second leading cause of death in children under the age of five. It also represents a significant unmet diagnostic need, particularly in the developing world.

Biotechnologists at the Sandia National Laboratories (Livermore, CA, USA) have developed a syndromic test that combines immunoassays and isothermal amplification-based molecular testing. Essentially a small, fully integrated syndromic panel, the test can go from stool sample to result using the next generation of a platform developed at Sandia called SpinDx. The SpinDx system, a centrifugal microfluidics diagnostics platform with integrated sample preparation. Among other enhancements, the newest version now incorporates non-contact temperature control using a medium-wave infrared heater.

The assay can detect three protein-based enterotoxins as well as DNA of three enteric pathogens. Specifically, it detects cholera toxin, Staphylococcal enterotoxin B, and Shiga-like toxin 1, as well as Campylobacter jejuni, Escherichia coli, and Salmonella typhimurium, in less than one hour. A panel of LAMP reactions was developed for the detection of C. jejuni E. coli, and S. typhimurium. In order to determine the limit of detection of the immunoassays, toxin solutions were diluted to concentrations of 1,000, 300, 100, 30, 10, 3 and 0 ng/mL and each was run in triplicate – with the exception of the highest concentration, which was run in duplicate.

The authors concluded that the core feature of the platform enabled multiplexed detections without the burdensome complexity found in similar centrifugal microfluidic devices is the non-contact heating system. The advantages of this system, in which the heat source is spatially separate from the disc, are numerous, including the viability of a simple, low-cost disc, since features such as embedded heating elements or actuation systems for bringing a heater into contact with the disc are not needed. The study was published originally published online on August 10, 2018, in the journal Biosensors and Bioelectronics.

Related Links:
Sandia National Laboratories

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Troponin T QC
Troponin T Quality Control
New
Treponema Pallidum Test
ZEUS IFA Fluorescent Treponemal Antibody-Absorption (FTA-ABS) Test System
New
Mumps Virus Test
ReQuest Mumps IgG

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.